225Ac-Rosopatamab (225Ac-CONV-01-α) is an alpha-radiolabeled monoclonal antibody targeting PSMA developed for the treatment of metastasized prostate cancer patients. This product is developed by Convergent Therapeutics, a partner of Aikido Pharma. The drug entered Phase I/II trial.